In this review, we summarise the current knowledge on the role of TGFβ1 and its novel modulator, LRG1, in different pathologies of cardiac remodelling and the potential of LRG1-targeted therapeutics for the treatment of heart failure. This evidence concerns the gene TGFB1 and heart failure.